Treatment of Patients with COVID-19-Induced Hypertension
Keywords:
COVID-19, coronavirus, angiotensin converting enzyme 2, renin-angiotensin-aldosterone system inhibitors, SARS-CoV-2, hypertensionAbstract
The novel coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus and known for inducing acute respiratory distress syndrome (ARDS), has affected more than 19 million individuals worldwide, resulting in approximately 0.7 million deaths as of August 2020. The fact that the virus uses angiotensin-converting enzyme 2 (ACE2) as a receptor to enter host cells, combined with the high prevalence of hypertension and other cardiovascular diseases among COVID-19 patients, has raised significant discussion regarding the management of such patients. This expert consensus from the Uzbek Medical Society for Arterial Hypertension reviews the current evidence on the relationship between COVID-19 and hypertension, the pathophysiological mechanisms of viral entry into target cells, and the use of renin-angiotensin-aldosterone system (RAAS) inhibitors in patients with hypertension and COVID-19.
References
Hall G., Laddu D.R., Phillips S.A. et al. The story of two pandemics: how will COVID-19 and global trends in physical inactivity and sedentary lifestyle affect each other? Prognostic Cardiovascular Dis 2020.
2. Employees associated with the global burden of disease risk factors. Global, regional and national comparative risk assessment of 84 behavioral, environmental, occupational and metabolic risks or risk clusters for 95 countries and territories, 1990-2017
3. Chazova I.E., Zhernakova Yu.V. Diagnosis and treatment of arterial hypertension. Systemic hypertension. 2019; 16 (1)
4. Muromtseva G.A., And Kontsevaya.V. Prevalence of risk factors for non-communicable diseases in the Russian population in 2012-2013 The results of the ESSAY-RF study. Cardiovascular therapy and prevention. 2014; 13 (6)
5. Mills K.T., Bundy J. Global differences in the prevalence of hypertension and its control: a systematic analysis of population studies from 90 countries. Circulation 2016;
6. Fighters S.A., Balanova Yu.A., Shalnova S.A., etc. Arterial hypertension among people aged 25-64 years: prevalence, awareness, treatment and control. Based on the materials of the ESSAY study. Cardiovascular therapy and prevention. 2014
7. Kearney P.M., Welton M. The global burden of hypertension: an analysis of global data. Lancet 2005
8. Ryu S., Chun B.K. Interim review of epidemiological characteristics of the new coronavirus 2019. Epid. Health-2020; 42
9. Wu F, Zhao S. A new coronavirus associated with human respiratory disease in China. Nature 2020.
10 . World Health Organization. New coronavirus (2019-nCoV). Situation Report22 (February 11, 2020).
11. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 7
12. Lu R, Zhao X. Genomic characterization and epidemiology of the new coronavirus 2019: implications for the origin of the virus and binding to receptors. Lancet 2020; 395
13. Shpakov A.O. Angiotensin-converting enzyme type 2, as a molecular mediator for cell infection with SARS-coronavirus-2 viruses. Russian Physiological Journal. IM. Sechenov. 2020; 106 (7).
14. Cyranoski D. The mystery of the animal source of the coronavirus is deepening. Nature 2020; 579 (7797): 18-9. DOI: 10.1038/d41586-020-00548- w
